Home › Companies › Vera Therapeutics, Inc. › 2025-2026

Vera Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Vera Therapeutics, Inc.’s Form 8-K, filed 2026-05-26 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
232Asset managers
1,347Fund votes
2026-05-21Meeting date

Proxy season: 2024-2025 2025-2026

Explore Vera Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Vera Therapeutics, Inc.

These tallies are Vera Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Vera Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-05-21
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Michael M. Morrisey, Ph.D.	45,288,710	--	--	13,814,671	2,863,469	Majority: yes
Elect Director: Patrick G. Enright	54,697,296	--	--	4,406,085	2,863,469	Majority: yes
Elect Director: James R. Meyers	58,946,269	--	--	157,112	2,863,469	Majority: yes
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm	61,834,842	44,710	87,298	--	--	Majority: yes
Proposal 3: Advisory Vote on Executive Compensation	56,585,568	2,433,537	84,276	--	2,863,469	Majority: yes

Source: Vera Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-05-26 — read the filing on EDGAR.

How asset managers voted at the Vera Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 232 asset managers that disclosed a Vera Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Vera Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-05-21.

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%

FOR: 56,585,568AGAINST: 2,433,537

Vera Therapeutics, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation”): 56,585,568 for, 2,433,537 against, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,782,904 outstanding shares: 79% for, 3% against (82% of the company cast a for/against vote).

The 230 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 91%

FOR: 90.5%AGAINST: 3.9%ABSTAIN: 5.6%NOT VOTED: 0.0%

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Vera Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
T. Rowe Price	7,864,766	0	0	For
Fidelity	5,691,756	0	0	For
Avoro Capital Advisors LLC	4,993,061	0	0	For
BlackRock	4,574,746	5,246	0	For
Vanguard	3,701,061	2	0	For
Kynam Capital Management, LP	0	0	3,337,893	Abstain
State Street	3,181,910	9,747	0	For
Deep Track Capital, LP	2,692,617	0	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	2,055,797	0	0	For
Eversept Partners, LP	1,728,485	0	0	For
AllianceBernstein	1,692,393	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,563,271	0	0	For
Sofinnova Investments, Inc.	1,440,942	0	0	For
American Century	0	1,132,981	0	Against
Vestal Point Capital, LP	1,079,213	0	0	For
Charles Schwab	1,055,504	0	0	For
PICTET ASSET MANAGEMENT SA	957,936	0	0	For
Point72	697,618	0	0	For
Integral Health Asset Management, LLC	589,081	0	0	For
Rock Springs Capital Management LP	503,585	0	0	For
Northern Trust	468,970	6,443	0	For
Candriam S.C.A.	0	475,335	0	Against
Woodline Partners LP	469,708	0	0	For
Nuveen	437,493	0	0	For
TIAA	424,493	0	0	For

Showing the 25 largest of 230 asset managers. See all 230 in the interactive database.

2. To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: James R. Meyers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-05-21.

Combines 7 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 58,946,269WITHHELD: 157,112

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: James R. Meyers”): 58,946,269 for, 157,112 withheld, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,782,904 outstanding shares: 82% for, 0.3% withheld (82% of the company cast a for/withheld vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (17,971,556 for, 0 against).

FOR 99.8%

FOR: 17,971,556 (99.9%)ABSTAIN: 25,399 (0.1%)

Largest asset managers voting on “To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of st” at Vera Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	3,286,052	0	For
Vanguard	3,197,621	0	For
Fidelity	2,919,238	0	For
BlackRock	2,564,567	0	For
State Street	2,031,076	0	For
American Century	540,540	0	For
Charles Schwab	524,826	0	For
AllianceBernstein	434,993	0	For
TIAA	424,493	0	For
AB DISCOVERY GROWTH FUND, INC.	265,992	0	For
Equitable	248,400	0	For
Voya	190,702	0	For
Brighthouse	110,246	25,399	For
QUANTITATIVE MASTER SERIES LLC	97,792	0	For
AIG/SunAmerica	97,375	0	For
Principal	96,696	0	For
Dimensional	90,833	0	For
Goldman Sachs	79,412	0	For
DWS	59,554	0	For
ProShares	57,782	0	For
Transamerica	53,604	0	For
ALPS ETF Trust	53,488	0	For
Calamos	46,974	0	For
Lincoln Financial	43,908	0	For
John Hancock	43,075	0	For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

3. To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Michael M. Morrissey, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-05-21.

Combines 8 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 45,288,710WITHHELD: 13,814,671

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael M. Morrisey, Ph.D.”): 45,288,710 for, 13,814,671 withheld, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,782,904 outstanding shares: 63% for, 19% withheld (82% of the company cast a for/withheld vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (13,688,265 for, 0 against).

FOR 76%ABSTAIN 24%

FOR: 13,688,265 (76.1%)ABSTAIN: 4,308,690 (23.9%)

Largest asset managers voting on “To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of st” at Vera Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	3,286,052	0	For
Vanguard	3,195,159	2,462	For
Fidelity	2,919,238	0	For
BlackRock	2,564,567	0	For
State Street	4,540	2,026,536	Abstain
American Century	0	540,540	Abstain
Charles Schwab	524,826	0	For
AllianceBernstein	0	434,993	Abstain
TIAA	424,493	0	For
AB DISCOVERY GROWTH FUND, INC.	0	265,992	Abstain
Equitable	107,025	141,375	Abstain
Voya	0	190,702	Abstain
Brighthouse	90,626	45,019	For
QUANTITATIVE MASTER SERIES LLC	97,792	0	For
AIG/SunAmerica	0	97,375	Abstain
Principal	0	96,696	Abstain
Dimensional	0	90,833	Abstain
Goldman Sachs	79,412	0	For
DWS	0	59,554	Abstain
ProShares	0	57,782	Abstain
Transamerica	53,604	0	For
ALPS ETF Trust	0	53,488	Abstain
Calamos	46,974	0	For
Lincoln Financial	0	43,908	Abstain
John Hancock	27,378	15,697	For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

4. To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of stockholders: Patrick G. Enright

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-05-21.

Combines 7 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 54,697,296WITHHELD: 4,406,085

Vera Therapeutics, Inc.’s own tally for this item (“Elect Director: Patrick G. Enright”): 54,697,296 for, 4,406,085 withheld, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,782,904 outstanding shares: 76% for, 6% withheld (82% of the company cast a for/withheld vote).

The 65 asset managers below cast 100% of the shares they voted on this item FOR (16,059,164 for, 0 against).

FOR 89%11%

FOR: 16,059,164 (89.2%)ABSTAIN: 1,937,791 (10.8%)

Largest asset managers voting on “To elect the three Class II directors named below to hold office until the Company's 2029 annual meeting of st” at Vera Therapeutics, Inc., 2025-2026
Asset manager	For	Abstain	Vote
T. Rowe Price	3,286,052	0	For
Vanguard	2,646,262	551,359	For
Fidelity	2,919,238	0	For
BlackRock	2,564,567	0	For
State Street	2,030,996	80	For
American Century	540,540	0	For
Charles Schwab	524,826	0	For
AllianceBernstein	0	434,993	Abstain
TIAA	424,493	0	For
AB DISCOVERY GROWTH FUND, INC.	0	265,992	Abstain
Equitable	107,025	141,375	Abstain
Voya	0	190,702	Abstain
Brighthouse	110,246	25,399	For
QUANTITATIVE MASTER SERIES LLC	97,792	0	For
AIG/SunAmerica	97,375	0	For
Principal	5,051	91,645	Abstain
Dimensional	0	90,833	Abstain
Goldman Sachs	79,412	0	For
DWS	0	59,554	Abstain
ProShares	57,782	0	For
Transamerica	53,604	0	For
ALPS ETF Trust	53,488	0	For
Calamos	46,974	0	For
Lincoln Financial	43,908	0	For
John Hancock	43,075	0	For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

5. TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-05-21.

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 61,834,842AGAINST: 44,710

Vera Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm”): 61,834,842 for, 44,710 against, per its Form 8-K filed 2026-05-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,782,904 outstanding shares: 86% for, 0.1% against (86% of the company cast a for/against vote).

The 64 asset managers below cast 99.9% of the shares they voted on this item FOR (17,986,114 for, 80 against).

FOR 99.8%

FOR: 17,986,114 (99.9%)AGAINST: 80 (0.0%)ABSTAIN: 25,399 (0.1%)

Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KPMG LLP AS THE INDEPENDENT REGIST” at Vera Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
T. Rowe Price	3,286,052	0	0	For
Vanguard	3,197,621	0	0	For
Fidelity	2,919,238	0	0	For
BlackRock	2,564,567	0	0	For
State Street	2,030,996	80	0	For
American Century	540,540	0	0	For
Charles Schwab	524,826	0	0	For
AllianceBernstein	434,993	0	0	For
TIAA	424,493	0	0	For
AB DISCOVERY GROWTH FUND, INC.	265,992	0	0	For
Equitable	248,400	0	0	For
Voya	190,702	0	0	For
Brighthouse	110,246	0	25,399	For
QUANTITATIVE MASTER SERIES LLC	97,792	0	0	For
AIG/SunAmerica	97,375	0	0	For
Principal	96,696	0	0	For
Dimensional	90,833	0	0	For
Goldman Sachs	79,412	0	0	For
DWS	59,554	0	0	For
ProShares	57,782	0	0	For
Transamerica	53,604	0	0	For
ALPS ETF Trust	53,488	0	0	For
Calamos	46,974	0	0	For
Lincoln Financial	43,908	0	0	For
John Hancock	43,075	0	0	For

Showing the 25 largest of 64 asset managers. See all 64 in the interactive database.

6. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.

SECTION 14A SAY-ON-PAY VOTES

Reported under meeting date 2026-03-24; no official results on file for that date.

13% fund support · no official result

13%AGAINST 87%

The 2 asset managers below cast 13% of the shares they voted on this item FOR (65,000 for, 428,391 against).

FOR: 65,000 (13.2%)AGAINST: 428,391 (86.8%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Vera Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
SCHRODER INVESTMENT MANAGEMENT GROUP	0	428,391	0	0	Against
Soviero Asset Management, LP	65,000	0	0	0	For

Largest Vera Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Vera Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 71,782,904 shares outstanding at the time of that meeting.

Top Vera Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	T. Rowe Price	10.96%
2	Fidelity	7.93%
3	Avoro Capital Advisors LLC	6.96%
4	BlackRock	6.38%
5	Vanguard	5.16%
6	Kynam Capital Management, LP	4.65%
7	State Street	4.45%
8	Deep Track Capital, LP	3.75%
9	DEERFIELD MANAGEMENT COMPANY, L.P.	2.86%
10	Eversept Partners, LP	2.41%

Reported Vera Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Vera Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	7.09%	13F
T. Rowe Price	6.37%	13F
Deep Track Capital, LP	5.46%	13G
Vanguard Group	4.97%	13F
State Street	4.69%	13F
Sofinnova Venture Partners X, L.P. ("SVP X")	3.89%	13D
FMR (Fidelity)	3.73%	13F
Geode Capital	2.19%	13F
Point72	1.71%	13F
Goldman Sachs	1.58%	13F

Percentages above are of 71,782,904 shares outstanding, as reported by Vera Therapeutics, Inc. on its Form 10-Q dated 2026-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vera Therapeutics, Inc.’s 10-Q dated 2026-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Vera Therapeutics, Inc.'s shareholder meeting held 2026-05-21, in the 2025-2026 proxy season, 232 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,347 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Vera Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-26.

Vera Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).